Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Q4 Revenues Inch Up While Losses Widen

NEW YORK, Feb 1 – Luminex's fourth quarter revenues increased slightly over the quarter, while its net losses widened, the company reported Thursday.

Luminex's Q4 2000 revenues totaled $3.5 million, up from $2.3 million for the year-ago quarter.

The company’s R&D expenses increased slightly to $2.9 million for the fourth quarter, compared to $2 million for the fourth quarter of 1999. Sales and administrative expenses increased to $3.1 million from $1.6 million for the same period last year.

Luminex's fourth quarter net losses also widened to $3.5 million, or 13 cents per share from $2.7 million, or 10 cents per share for the year-ago quarter. These losses met Wall Street’s expectations, based on a survey of three brokers conducted by FirstCall/Thomson Financial.

During the fourth quarter, the company sold 120 of its Luminex 100 benchtop high throughput assay systems, increasing its installed base to 389.

The Luminex 100 systems employ the company's LabMap technology, which assays nucleic acids, antigen-antibody binding, enzymes, and other receptor-ligand interactions on the surface of microbeads.

The company’s fourth quarter report ends a year in which Luminex gained $77 million in an initial public offering, and posted total revenues of $8.6 million.

“2000 was a very exciting year for Luminex," said CEO Mark Chandler in a statement. " We completed a successful initial public offering, significantly increased our installed base of systems, entered into additional development and distribution partnerships with key industry players, extended our LabMap technology to new products and had our strategic partners launch the first commercial kits based on our technology.”

Luminex’s stock was up 1.52% today to 28 1/8. The company’s stock hit a high of 64 1/8 in July.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.